Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Survival outcomes favored the higher dose: more than 93% of patients in the 70 Gy group were alive one year after treatment, ...

Dr. Jared Weiss details the importance of continued research into novel therapies for patients with lung cancer.

The trial enrolled patients with NSCLC that had PD-L1 expression on 25% or more cells whose tumours had been completely removed with surgery. Imfinzi is already approved for unresectable ...

It sounds too simple to be true. Exercise works just as effectively as a drug to slash the risk of dying from bowel cancer, ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

only around a quarter of patients live beyond five years. In ADRIATIC, Imfinzi achieved a statistically significant improvement in both progression-free survival (PFS) and overall survival (OS ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.